Bernie Sanders lifts hold on NIH nom­i­nee fol­low­ing Re­gen­eron price con­ces­sions

Last year
People
Coronavirus

Marc Tessier-Lav­i­gne steps down from Re­gen­eron board

Last year
People

Up­dat­ed: No­var­tis dis­con­tin­ues lead Gy­ro­scope gene ther­a­py af­ter $800M+ buy­out

Last year
R&D
Cell/Gene Tx

Mod­er­na strikes $1.8B can­cer re­search deal with Im­mat­ics 

Last year
Deals

NASH com­pa­ny Madri­gal names for­mer Sanofi ex­ec Bill Si­bold as new CEO

Last year
People

Gilead, As­traZeneca/Dai­ichi Sankyo of­fer first look at TROP2 AD­Cs in first-line lung can­cer as ri­val­ry heats up 

Last year
R&D

Cri­net­ics re­veals pos­i­tive topline pri­ma­ry and sec­ondary end­point da­ta in PhI­II acromegaly tri­al

Last year
R&D

As­traZeneca's Tagris­so/chemo com­bo staves off lung can­cer for al­most nine months. But will side ef­fects lim­it its ...

Last year
R&D

Biotech megarounds ga­lore; New lead­ers at No­var­tis, Bio­gen; State of play for GLP-1 in NASH; In­side Il­lu­mi­na’s CEO ...

Last year
Weekly

Kroger inks $1.4B set­tle­ment deal for opi­oid law­suits

Last year
Pharma
Law

New bi­par­ti­san House bill in­cludes ma­jor PBM re­forms

Last year
Pharma
Law

FDA main­tains Covid flex­i­bil­i­ties for IRB re­view of ex­pand­ed ac­cess drugs for in­di­vid­u­als

Last year
Pharma
FDA+

Ex­pe­dit­ed CMC readi­ness pi­lot in­creas­es com­mu­ni­ca­tions be­tween FDA and spon­sors

Last year
FDA+
Manufacturing

Citius Phar­ma­ceu­ti­cals looks to re­file for­mer Ei­sai can­cer drug in ear­ly 2024

Last year
Pharma
FDA+

Medicare en­rollees paid far more for drugs than plan spon­sors did in 2021, GAO says

Last year
Pharma
FDA+

No­var­tis ad­justs busi­ness unit names in prepa­ra­tion for San­doz gener­ics and biosim­i­lars spin­off

Last year
Pharma
Marketing

CDC en­cour­ages fall flu vac­ci­na­tions to tame symp­tom sever­i­ty in ‘Wild to Mild’ cam­paign

Last year
Pharma
Marketing

MIT sci­en­tists look to un­lock po­ten­tial of ‘self-ad­ju­vant­i­ng’ mR­NA vac­cines in mice

Last year
R&D
Pharma

Chi­nese cell ther­a­py biotech de­vel­op­ing TIL ther­a­pies rais­es $60M Se­ries B

Last year
Financing
China

ProMIS Neu­ro­sciences se­cures $20M+ PIPE; Beam Ther­a­peu­tics re­veals da­ta ahead of IND

Last year
News Briefing

Man­u­fac­tur­ing tweaks to sub­cu­ta­neous Tecen­triq de­lay Roche's US launch, CMC process­es to be up­dat­ed by year’s end

Last year
Manufacturing

Verge Ge­nomics teams up with As­traZeneca in drug dis­cov­ery deal

Last year
Deals

Bangladeshi glau­co­ma eye drop man­u­fac­tur­er banned from sup­ply­ing prod­ucts in Eu­rope

Last year
Manufacturing

Glyscend taps CEO to lead oral obe­si­ty, type 2 di­a­betes can­di­date; Ex-Travec­ta chief bounces back af­ter com­pa­ny ...

Last year
Peer Review
First page Previous page 283284285286287288289 Next page Last page
A service from the Financial Times